Chinese General Practice ›› 2023, Vol. 26 ›› Issue (30): 3772-3779.DOI: 10.12114/j.issn.1007-9572.2023.0202
• Original Research • Previous Articles Next Articles
Received:
2023-03-08
Revised:
2023-05-23
Published:
2023-10-20
Online:
2023-05-31
Contact:
ZHU Shuchai
通讯作者:
祝淑钗
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0202
组别 | 例数 | 性别(男/女) | 年龄〔例(%)〕 | ECOG评分〔例(%)〕 | 肿瘤部位〔例(%)〕 | 肿瘤长度〔例(%)〕 | T分期〔例(%)〕 | N分期〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<64岁 | ≥64岁 | 0分 | 1~2分 | 颈胸上段 | 胸中下段 | <6 cm | ≥6 cm | T1/T2期 | T3/T4期 | N0期 | N1/N2期 | |||
单纯同步放化疗组 | 87 | 60/27 | 39(44.8) | 48(55.2) | 29(33.3) | 58(66.7) | 28(32.2) | 59(67.8) | 43(49.4) | 44(50.6) | 26(29.9) | 61(80.1) | 16(18.4) | 71(81.6) |
联合巩固化疗组 | 136 | 96/40 | 68(50.0) | 68(50.0) | 53(39.0) | 83(61.0) | 54(39.7) | 82(60.3) | 72(52.9) | 64(47.1) | 41(30.1) | 95(69.9) | 28(20.6) | 108(79.4) |
χ2值 | 0.066 | 0.569 | 0.725 | 1.044 | 0.263 | 0.002 | 0.162 | |||||||
P值 | 0.797 | 0.451 | 0.394 | 0.307 | 0.608 | 0.967 | 0.688 | |||||||
组别 | TNM分期〔例(%)〕 | 放疗剂量〔例(%)〕 | 照射方式〔例(%)〕 | 化疗方案〔例(%)〕 | NRS 2002评分〔例(%)〕 | 临床疗效〔例(%)〕 | ||||||||
Ⅱ期 | Ⅲ期 | <60.8 Gy | ≥60.8 Gy | ENI | IFI | TP | FP | <3分 | ≥3分 | CR | PR+SD | |||
单纯同步放化疗组 | 43(49.4) | 44(50.6) | 48(55.2) | 39(44.8) | 40(46.0) | 47(54.0) | 61(70.1) | 26(29.9) | 65(74.7) | 22(25.3) | 28(32.2) | 59(67.8) | ||
联合巩固化疗组 | 74(54.4) | 62(45.6) | 63(46.3) | 73(53.7) | 72(52.9) | 64(47.1) | 91(66.9) | 45(33.1) | 107(78.7) | 29(21.3) | 33(24.3) | 103(75.7) | ||
χ2值 | 0.529 | 1.662 | 1.029 | 0.251 | 0.473 | 1.674 | ||||||||
P值 | 0.467 | 0.197 | 0.310 | 0.616 | 0.492 | 0.196 |
Table 1 Comparison of clinical data between the two groups of patients
组别 | 例数 | 性别(男/女) | 年龄〔例(%)〕 | ECOG评分〔例(%)〕 | 肿瘤部位〔例(%)〕 | 肿瘤长度〔例(%)〕 | T分期〔例(%)〕 | N分期〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<64岁 | ≥64岁 | 0分 | 1~2分 | 颈胸上段 | 胸中下段 | <6 cm | ≥6 cm | T1/T2期 | T3/T4期 | N0期 | N1/N2期 | |||
单纯同步放化疗组 | 87 | 60/27 | 39(44.8) | 48(55.2) | 29(33.3) | 58(66.7) | 28(32.2) | 59(67.8) | 43(49.4) | 44(50.6) | 26(29.9) | 61(80.1) | 16(18.4) | 71(81.6) |
联合巩固化疗组 | 136 | 96/40 | 68(50.0) | 68(50.0) | 53(39.0) | 83(61.0) | 54(39.7) | 82(60.3) | 72(52.9) | 64(47.1) | 41(30.1) | 95(69.9) | 28(20.6) | 108(79.4) |
χ2值 | 0.066 | 0.569 | 0.725 | 1.044 | 0.263 | 0.002 | 0.162 | |||||||
P值 | 0.797 | 0.451 | 0.394 | 0.307 | 0.608 | 0.967 | 0.688 | |||||||
组别 | TNM分期〔例(%)〕 | 放疗剂量〔例(%)〕 | 照射方式〔例(%)〕 | 化疗方案〔例(%)〕 | NRS 2002评分〔例(%)〕 | 临床疗效〔例(%)〕 | ||||||||
Ⅱ期 | Ⅲ期 | <60.8 Gy | ≥60.8 Gy | ENI | IFI | TP | FP | <3分 | ≥3分 | CR | PR+SD | |||
单纯同步放化疗组 | 43(49.4) | 44(50.6) | 48(55.2) | 39(44.8) | 40(46.0) | 47(54.0) | 61(70.1) | 26(29.9) | 65(74.7) | 22(25.3) | 28(32.2) | 59(67.8) | ||
联合巩固化疗组 | 74(54.4) | 62(45.6) | 63(46.3) | 73(53.7) | 72(52.9) | 64(47.1) | 91(66.9) | 45(33.1) | 107(78.7) | 29(21.3) | 33(24.3) | 103(75.7) | ||
χ2值 | 0.529 | 1.662 | 1.029 | 0.251 | 0.473 | 1.674 | ||||||||
P值 | 0.467 | 0.197 | 0.310 | 0.616 | 0.492 | 0.196 |
变量 | 赋值 |
---|---|
性别 | 男=0,女=1 |
年龄 | <64岁=0,≥64岁=1 |
ECOG评分 | 0分=0,1~2分=1 |
肿瘤部位 | 颈胸上段=0,胸中下段=1 |
肿瘤长度 | <6 cm=0,≥6 cm=1 |
T分期 | T1/T2期=0,T3/T4期=1 |
N分期 | N0期=0,N1/N2期=1 |
TNM分期 | Ⅱ期=0,Ⅲ期=1 |
放疗剂量 | <60.8 Gy=0,≥60.8 Gy=1 |
照射方式 | ENI=0,IFI=1 |
化疗方案 | TP=0,FP=1 |
NRS 2002评分 | <3分=0,≥3分=1 |
临床疗效 | CR=0,PR+SD=1 |
治疗方式 | 单纯同步放化疗=0,联合巩固化疗=1 |
Table 2 Variable assignments for univariate and multivariate Cox hazard regression analysis of influencing factors for prognosis in patients with stage Ⅱ-Ⅲ ESCC
变量 | 赋值 |
---|---|
性别 | 男=0,女=1 |
年龄 | <64岁=0,≥64岁=1 |
ECOG评分 | 0分=0,1~2分=1 |
肿瘤部位 | 颈胸上段=0,胸中下段=1 |
肿瘤长度 | <6 cm=0,≥6 cm=1 |
T分期 | T1/T2期=0,T3/T4期=1 |
N分期 | N0期=0,N1/N2期=1 |
TNM分期 | Ⅱ期=0,Ⅲ期=1 |
放疗剂量 | <60.8 Gy=0,≥60.8 Gy=1 |
照射方式 | ENI=0,IFI=1 |
化疗方案 | TP=0,FP=1 |
NRS 2002评分 | <3分=0,≥3分=1 |
临床疗效 | CR=0,PR+SD=1 |
治疗方式 | 单纯同步放化疗=0,联合巩固化疗=1 |
项目 | OS | LRRFS | DMFS | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
性别 | 0.712(0.491,1.034) | 0.074 | 0.694(0.481,1.002) | 0.050 | 0.719(0.502,1.030) | 0.072 |
年龄 | 0.771(0.553,1.074) | 0.123 | 0.733(0.529,1.015) | 0.061 | 0.798(0.579,1.098) | 0.166 |
ECOG评分 | 1.224(0.879,1.703) | 0.231 | 1.266(0.915,1.752) | 0.155 | 1.316(0.957,1.811) | 0.092 |
肿瘤部位 | 2.004(1.387,2.896) | <0.001 | 1.839(1.288,2.624) | 0.001 | 1.953(1.372,2.780) | <0.001 |
肿瘤长度 | 1.637(1.173,2.286) | 0.004 | 1.593(1.148,2.211) | 0.005 | 1.586(1.150,2.187) | 0.005 |
T分期 | 1.862(1.263,2.745) | 0.002 | 1.728(1.187,2.514) | 0.004 | 1.893(1.299,2.758) | 0.001 |
N分期 | 1.873(1.176,2.984) | 0.008 | 1.642(1.058,2.547) | 0.027 | 1.943(1.244,3.035) | 0.004 |
TNM分期 | 2.069(1.480,2.892) | <0.001 | 1.941(1.398,2.696) | <0.001 | 2.194(1.587,3.033) | <0.001 |
放疗剂量 | 0.866(0.622,1.206) | 0.395 | 0.876(0.632,1.213) | 0.425 | 0.846(0.615,1.165) | 0.307 |
照射方式 | 1.779(1.272,2.488) | 0.001 | 1.782(1.281,2.479) | 0.001 | 2.024(1.462,2.802) | <0.001 |
化疗方案 | 1.225(0.864,1.739) | 0.255 | 1.150(0.813,1.626) | 0.429 | 1.199(0.853,1.686) | 0.296 |
NRS 2002评分 | 1.609(1.115,2.323) | 0.011 | 1.502(1.043,2.164) | 0.029 | 1.655(1.158,2.365) | 0.006 |
临床疗效 | 1.959(1.300,2.954) | 0.001 | 1.883(1.264,2.804) | 0.002 | 1.955(1.320,2.893) | 0.001 |
治疗方式 | 0.788(0.563,1.103) | 0.165 | 0.864(0.620,1.205) | 0.390 | 0.829(0.599,1.149) | 0.261 |
Table 3 Univariate Cox hazard regression analysis of influencing factors for prognosis in patients with stage Ⅱ-Ⅲ ESCC
项目 | OS | LRRFS | DMFS | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
性别 | 0.712(0.491,1.034) | 0.074 | 0.694(0.481,1.002) | 0.050 | 0.719(0.502,1.030) | 0.072 |
年龄 | 0.771(0.553,1.074) | 0.123 | 0.733(0.529,1.015) | 0.061 | 0.798(0.579,1.098) | 0.166 |
ECOG评分 | 1.224(0.879,1.703) | 0.231 | 1.266(0.915,1.752) | 0.155 | 1.316(0.957,1.811) | 0.092 |
肿瘤部位 | 2.004(1.387,2.896) | <0.001 | 1.839(1.288,2.624) | 0.001 | 1.953(1.372,2.780) | <0.001 |
肿瘤长度 | 1.637(1.173,2.286) | 0.004 | 1.593(1.148,2.211) | 0.005 | 1.586(1.150,2.187) | 0.005 |
T分期 | 1.862(1.263,2.745) | 0.002 | 1.728(1.187,2.514) | 0.004 | 1.893(1.299,2.758) | 0.001 |
N分期 | 1.873(1.176,2.984) | 0.008 | 1.642(1.058,2.547) | 0.027 | 1.943(1.244,3.035) | 0.004 |
TNM分期 | 2.069(1.480,2.892) | <0.001 | 1.941(1.398,2.696) | <0.001 | 2.194(1.587,3.033) | <0.001 |
放疗剂量 | 0.866(0.622,1.206) | 0.395 | 0.876(0.632,1.213) | 0.425 | 0.846(0.615,1.165) | 0.307 |
照射方式 | 1.779(1.272,2.488) | 0.001 | 1.782(1.281,2.479) | 0.001 | 2.024(1.462,2.802) | <0.001 |
化疗方案 | 1.225(0.864,1.739) | 0.255 | 1.150(0.813,1.626) | 0.429 | 1.199(0.853,1.686) | 0.296 |
NRS 2002评分 | 1.609(1.115,2.323) | 0.011 | 1.502(1.043,2.164) | 0.029 | 1.655(1.158,2.365) | 0.006 |
临床疗效 | 1.959(1.300,2.954) | 0.001 | 1.883(1.264,2.804) | 0.002 | 1.955(1.320,2.893) | 0.001 |
治疗方式 | 0.788(0.563,1.103) | 0.165 | 0.864(0.620,1.205) | 0.390 | 0.829(0.599,1.149) | 0.261 |
项目 | OS | LRRFS | DMFS | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
肿瘤部位 | 1.402(0.936,2.099) | 0.101 | 1.228(0.825,1.829) | 0.311 | 1.241(0.838,1.839) | 0.281 |
肿瘤长度 | 0.962(0.618,1.498) | 0.864 | 1.040(0.672,1.610) | 0.861 | 0.885(0.581,1.347) | 0.568 |
T分期 | 1.264(0.768,2.080) | 0.356 | 1.111(0.677,1.823) | 0.677 | 1.280(0.790,2.072) | 0.316 |
N分期 | 1.399(0.871,2.246) | 0.165 | 1.224(0.780,1.921) | 0.379 | 1.471(0.933,2.318) | 0.096 |
TNM分期 | 1.480(1.008,2.174) | 0.046 | 1.439(0.985,2.103) | 0.060 | 1.606(1.113,2.317) | 0.011 |
照射方式 | 1.350(0.938,1.944) | 0.106 | 1.478(1.024,2.134) | 0.037 | 1.640(1.148,2.342) | 0.007 |
NRS 2002评分 | 1.497(1.029,2.177) | 0.035 | 1.363(0.937,1.982) | 0.105 | 1.565(1.084,2.259) | 0.017 |
临床疗效 | 1.890(1.252,2.853) | 0.002 | 1.842(1.236,2.746) | 0.003 | 1.986(1.337,2.951) | 0.001 |
Table 4 Multivariate Cox hazard regression analysis of influencing factors of prognosis in patients with stage Ⅱ-Ⅲ ESCC
项目 | OS | LRRFS | DMFS | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
肿瘤部位 | 1.402(0.936,2.099) | 0.101 | 1.228(0.825,1.829) | 0.311 | 1.241(0.838,1.839) | 0.281 |
肿瘤长度 | 0.962(0.618,1.498) | 0.864 | 1.040(0.672,1.610) | 0.861 | 0.885(0.581,1.347) | 0.568 |
T分期 | 1.264(0.768,2.080) | 0.356 | 1.111(0.677,1.823) | 0.677 | 1.280(0.790,2.072) | 0.316 |
N分期 | 1.399(0.871,2.246) | 0.165 | 1.224(0.780,1.921) | 0.379 | 1.471(0.933,2.318) | 0.096 |
TNM分期 | 1.480(1.008,2.174) | 0.046 | 1.439(0.985,2.103) | 0.060 | 1.606(1.113,2.317) | 0.011 |
照射方式 | 1.350(0.938,1.944) | 0.106 | 1.478(1.024,2.134) | 0.037 | 1.640(1.148,2.342) | 0.007 |
NRS 2002评分 | 1.497(1.029,2.177) | 0.035 | 1.363(0.937,1.982) | 0.105 | 1.565(1.084,2.259) | 0.017 |
临床疗效 | 1.890(1.252,2.853) | 0.002 | 1.842(1.236,2.746) | 0.003 | 1.986(1.337,2.951) | 0.001 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准草案[J]. 中华放射肿瘤学杂志,2010,19(3):179-180. DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.
|
[12] |
中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2022年版)[J]. 国际肿瘤学杂志,2022,49(11):12-25. DOI:10.3760/cma.j.cn371439-20221011-00129.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[1] | XUE Chongxiang, LU Xingyu, LIU Zhening, DONG Huijing, ZHENG Yumin, CUI Huijuan. Dynamic Monitoring of Gene Changes and Its Prognostic Value in Lung Cancer Patients [J]. Chinese General Practice, 2023, 26(36): 4527-4534. |
[2] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[3] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[4] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[5] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[6] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[7] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[8] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[9] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[10] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[11] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[12] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[13] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[14] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[15] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||